Cereno Scientific has reported encouraging 12-month safety and clinical observations [...]

Cereno Scientific has reported initial long-term safety findings from a [...]

As Rare Disease Day 2026 shines a spotlight on patients [...]

Cereno Scientific has broadened the clinical development focus of its [...]

Cereno Scientific has completed the last patient’s last visit in [...]

Cereno Scientific has published the first peer-reviewed paper describing its [...]

Cereno Scientific has submitted the clinical trial protocol for its [...]

Cereno Scientific, a biotechnology company pioneering treatments for rare cardiovascular [...]

Selection of CRO marks key milestone in advancing CS1 as [...]